Positive Results from an Early-Stage Drug Trial

admin • March 25, 2015

Share this article

On Friday, March 20, positive early-stage clinical trial results for aducanumab (BIIB037, Biogen) were presented at the International Conference on Alzheimer’s and Parkinson’s Diseases in Nice, France.

There were two types of participants in the Phase 1b clinical trial : people with high levels of amyloid in their brain, and people with early Alzheimer’s disease. A total of 166 individuals were split into multiple treatment groups and a placebo group. Each treatment group received a different dosage of the drug for up to 54 weeks. The individual treatment groups were only 30-33 people each, with 40 in the placebo group.

< Older Post

 Newer Post >

Recent Posts

Three people sit around a round table, smiling and working together on papers with pens in a bright, outdoor setting.

Top Cognitive Activities for Seniors in Memory Care That Boost Brain Health

By admin • January 21, 2026
Cognitive activities are more than just pastimes for seniors in memory care. They play a crucial role in stimulating the brain, promoting independence, and improving emotional well-being.
An adult and an elderly person embracing warmly with their eyes closed, resting their heads together.

How to Prepare Your Loved One for Memory Care Transition

By admin • January 7, 2026
Preparing a loved one to move into memory care is a deeply emotional process. Whether your family member has Alzheimer’s, dementia, or another form of cognitive decline, this transition can […]
A group of people wearing grass skirts and leis pose in a hallway, smiling with their arms raised as if performing.

River Edge Celebrates 10 Years of Compassionate Memory Care

By admin • November 12, 2025
PR Newswire – River Edge, N.J., Nov. 10, 2025 Regency Memory Care Club, a pioneer in social and cognitive engagement for individuals with Alzheimer’s disease and other forms of dementia, […]
Show More